- 1 Title: Placental PFAS concentrations are associated with perturbations of placental DNA methylation at
- 2 loci with important roles on cardiometabolic health.
- 3

4 Authors and Affiliations:

- Todd M. Everson^{1,2,*}, Neha Sehgal¹, Dana Boyd Barr¹, Parinya Panuwet¹, Volha Yakimavets¹, Cynthia
 Perez¹, Kartik Shankar³, Stephanie M. Eick^{1,2}, Kevin J. Pearson⁴, Aline Andres^{5,6}
- Gangarosa Department of Environmental Health, Emory University Rollins School of Public
 Health, Atlanta, GA, USA
- 9 2. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA,
 10 USA
- Department of Pediatrics, Section of Nutrition, University of Colorado School of Medicine, Aurora, CO
- Department of Pharmacology & Nutritional Sciences, University of Kentucky College of Medicine
- 15 5. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR
- 16 6. Arkansas Children's Nutrition Center, Little Rock, AR

17 Corresponding Author Contact Information:

- 18 *Correspondence should be addressed to Todd M. Everson (<u>Todd.M.Everson@Emory.edu</u>), PhD,
- 19 Gangarosa Department of Environmental Health, Emory University Rollins School of Public Health,
- 20 1518 Clifton Road NE, Mailstop 1518-002-2BB, Atlanta, GA 30322; Phone: 404.727.8136; Fax:
- 21 404.727.8744
- 22 Key Words: epigenetics, DNA methylation, PFAS, placenta, prenatal
- 23
- 24
- 25

26 Abstract:

The placenta is crucial for fetal development, is affected by PFAS toxicity, and evidence is accumulating 27 that gestational PFAS perturb the epigenetic activity of the placenta. Gestational PFAS exposure is can 28 29 adversely affect offspring, yet individual and cumulative impacts of PFAS on the placental epigenome 30 remain underexplored. Here, we conducted an epigenome-wide association study (EWAS) to examine the 31 relationships between placental PFAS levels and DNA methylation in a cohort of mother-infant dyads in 32 Arkansas. We measured 17 PFAS in human placental tissues and quantified placental DNA methylation 33 levels via the Illumina EPIC Microarray. We tested for differential DNA methylation with individual 34 PFAS, and with mixtures of multiple PFAS. Our results demonstrated that numerous epigenetic loci were 35 perturbed by PFAS, with PFHxS exhibiting the most abundant effects. Mixture analyses suggested cumulative effects of PFOA and PFOS, while PFHxS may act more independently. We additionally 36 37 explored whether sex-specific effects may be present and concluded that future large studies should 38 explicitly test for sex-specific effects. The genes that are annotated to our PFAS-associated epigenetic loci 39 are primarily involved in growth processes and cardiometabolic health, while some genes are involved in 40 neurodevelopment. These findings shed light on how prenatal PFAS exposures affect birth outcomes and children's health, emphasizing the importance of understanding PFAS mechanisms in the in-utero 41 42 environment.

44 Introduction:

45 Per- and polyfluoroalkyl substances (PFAS) are man-made chemicals that are ubiquitously used in consumer products, food packaging, and firefighting foams. These chemicals are of significant 46 47 environmental concerns due to their pervasiveness in everyday products and their persistence in the 48 environment and human biomatrices [1]. Human exposure to PFAS is linked to several health outcomes, 49 including multiple cardiometabolic conditions, and adverse effects during pregnancy (e.g., birth and 50 developmental outcomes) [2]. Several mechanisms could explain these intergenerational effects, 51 including direct fetal exposure from maternal circulation or by disrupting maternal physiology including 52 placental development and function. Some quantity of PFAS from maternal circulation pass through the placenta to reach many fetal organ systems, and PFAS bioaccumulate in the placenta throughout gestation 53 54 [3]. PFAS accumulation in the placenta may have consequences on placental function and moderation of 55 the in-utero environment.

A recent review Szilagyi et al (2020) highlighted a likely role for PFAS interactions with 56 57 peroxisome proliferator-activated receptors (PPARs), which may impact placental functions [4]. PPARs 58 are nuclear receptors that broadly regulate lipid, hormone and glucose metabolism [5], and are associated 59 with placentation and trophoblast differentiation [4]. PPAR activities in the placenta serve many roles, 60 and influences the expression of multiple genes and pathways involved in placental development [6]. Additionally, epigenetic alterations, such as changes in DNA methylation, may impact placental function, 61 affect birth outcomes and children's health, since other persistent organic pollutants (POPs) have such 62 63 effects [7]. A few recent studies have begun to explore the impact of prenatal PFAS on the human 64 placental epigenome. Wang et al (2023) used a targeted gene approach and global methylation analysis, to 65 show that placental PFAS levels were negatively associated LINE-1 methylation and with CpGs in the 66 nuclear receptor subfamily 3 group C member 1 (NR3C1) gene; and that PFAS associations with 67 placental methylation and birth outcomes may be modified by sex [8]. An epigenome-wide association 68 study (EWAS) of several persistent organic pollutants in maternal plasma, including PFAS, found that several individual PFAS were associated with differences in DNA methylation levels of 39 CpG sites [9]. 69

Another study examined relationships between maternal plasma PFAS concentrations with placental 70 71 DNAm differences using reduced representation bisulfite sequencing in a sub-sample (n=16), then 72 demonstrated more statistically robust associations with three of these five candidates in the full cohort 73 (n=345) [10]. Thus, to date, studies of the impacts of gestational PFAS exposure on the human placental 74 methylome have primarily utilized maternal plasma as an exposure biomarker, or when placental PFAS 75 levels were quantified, they were only examined in association with targeted genes and features. 76 Given that the placenta is likely affected by PFAS toxicity, and individual PFAS have been 77 shown to be associated with DNA methylation differences in a handful of placental epigenomic studies. there is a need to further characterize the cumulative impacts of PFAS in the placenta on the placental 78 79 epigenome. Such studies which better reflect real world PFAS exposure patterns can help to elucidate the 80 mechanisms by which PFAS exert their effects on placental function and the *in-utero* environment. Here, 81 we performed an EWAS of the relationships between placental PFAS concentrations with differences in 82 DNA methylation. We first examined these relationships for each individual PFAS compound that was uniformly detected in our sample, then examined the associations with the overall mixture of PFAS on 83 84 DNA methylation, and last explored whether there was evidence of sex-specific effects. 85

87 Methods:

88 Study Population

This study was performed as part of the Glowing Study in Little Rock, Arkansas, which recruited 89 pregnant women prior to gestational week 10, and enrollment occurred between 2010 and 2014 90 91 (www.clinicaltrials.gov, ID #NCT03281850) [11, 12]. This longitudinal observational cohort consisted of 92 300 second parity dyads, from singleton pregnancies, with mothers who were at least 21 years of age. 93 Exclusion criteria included self-reported pre-existing medical conditions, sexually transmitted infections, 94 medical complications, reported smoking or alcohol use during pregnancy, or medication use during 95 pregnancy known to influence fetal growth (e.g. gestational diabetes, thyroid disease, pre-eclampsia) and 96 conceptions aided with fertility treatment. Infants included in the analyses had no medical conditions and 97 required no medications known to influence growth or development of the fetus. This study included all dyads where placental samples were collected, and where PFAS and DNA methylation quantification 98 99 passed quality control (n=151). All study participants provided informed, written consent and the study 100 was approved by the University of Arkansas for Medical Sciences Institutional Review Board. 101 Placental Collection and Processing Placentas were collected within 30 minutes of delivery and processed within 2 hours, those with 102 103 severe placental pathologies were excluded. Placental tissues from the villous core, maternal and fetal 104 sides were separately collected from 6 random sites (~1 sq. in) and washed thrice in ice-cold PBS to 105 remove maternal blood. Samples were then flash-frozen. For comprehensive representation of the entire 106 placenta, ~1 g of pooled tissue from all six collection sites (each compartment separately) was frozen in 107 liquid nitrogen and pulverized. Tissue samples were pooled from all regions of the villous core and the 108 same pooled pulverized sample was used for all -omics and PFAS analysis.

109 Placental PFAS Quantification

Placental samples were randomized prior to analysis to reduce analytical batch effects. Powdered
placental tissue (0.2-0.7mg per sample), was spiked with isotopically labeled analogues of target PFAS,
then homogenized in methanol. The 17 target PFAS include: perfluorohexanoic acid (PFHxA),

113 perfluorohexane sulfonic acid (PFHxS), perfluoroheptanoic acid (PFHpA), perfluorooctanoic acid 114 (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorooctane sulfonamide (PFOSA), nmethylperfluoro-1-octanesulfonamidoacetic acid (MePFOSAA), perfluorononanoic acid (PFNA), 115 116 perfluorodecanoic acid (PFDA), perfluorodecane sulfonic acid (PFDS), perfluoroundecanoic acid 117 (PFUnDA), perfluorododecanoic acid (PFDoDA), perfluoropentanoic acid (PFPeA), n-ethylperfluoro-1-118 octanesulfonamidoacetic acid (EtPFOSAA), hexafluoropropyleneoxide dimer acid (HFPO-DA; Gen X), 119 perfluoroheptane sulfonic acid (PFHpS), and perfluorobutanesulfonic acid (PFBS). The homogenized 120 samples were centrifuged, and the methanol layer was separated from the placenta tissue. The methanolic 121 fraction was then evaporated to almost dryness and mixed with a mixture of methanol: 0.1M formic acid (40:60, v/v). The samples were introduced onto a Strata RP on-line extraction column (2.1 x 20 mm). The 122 on-line extraction column was washed with 0.1 M formic acid: acetonitrile (90:10, V/V). Then, the target 123 124 analytes were transferred to a Betasil C18 analytical column (6 x 150 mm) for chromatographic 125 separation. The target PFAS were analyzed using high-performance liquid chromatography-tandem mass 126 spectrometry (LC-MS/MS) with electrospray ionization. The analyte concentrations were calculated using 127 isotope dilution calibration. The unknown samples were analyzed alongside a replicate of solvent-based blanks for background evaluation and quality control materials (2 levels) for precision and accuracy 128 129 assurance.

Two samples that had insufficient quantity of tissue to perform quantification were excluded from
further analyses, yielding a sample size of 151 for analyses of placental PFAS levels. Concentrations of
five PFAS (PFHxS, PFOS, PFOA, PFNA, and PFDA) were detectable in over 70% of placental samples.
All downstream analyses focused on these five PFAS. Concentrations below the limit of detection (LOD)
were imputed via LOD/√2 and data were natural log-transformed prior to performing statistical analyses. *Placental DNA methylation Quantification*DNA extraction was performed using PureLink Genomic DNA isolation reagents (Thermo

Fisher). DNA was quantified with Qubit dsDNA quantification assays (Thermo Fisher, Waltham, MA,
USA), then aliquoted into standardized concentrations to allow for a total mass of 500 ng of DNA.

139	Samples were randomly distributed across 96-well plates, rows, and chips to reduce the potential for
140	batch effects. The Emory University Integrated Genomics Core performed bisulfite conversion using the
141	EZ DNA Methylation Kit (Zymo Research, Irvine, CA) and measured DNAm throughout the genome
142	using the Illumina MethylationEPIC Beadarray (Illumina, San Diego, CA) following the manufacturer's
143	protocol. All 153 placental DNA samples passed quality control, with no samples yielding more than 1%
144	or of probes with detection p values > 0.05. Functional normalization [13] and beta-mixture quantile
145	(BMIQ) normalization were performed [14] to normalize technical differences on the arrays and correct
146	for different distributions between type-I and type-II probe designs. Then probes on the X and Y
147	chromosomes, those that had single nucleotide polymorphisms (SNP) within the binding region, and
148	those that could cross-hybridize to other regions of the genome [15] were excluded.
149	Statistical Analyses
150	All statistical analyses were performed in RStudio (version 4.3.0 or above). Frequencies and
151	arithmetic means and standard deviations (SDs) were used to describe the distribution of demographic
152	variables. Geometric means and SDs and selected percentiles were used to summarize PFAS
153	concentrations. Violin plots were used to visualize the distributions of natural log transformed PFAS.
154	Spearman correlation coefficients were used to determine the relation between each placental PFAS.
155	Prior to conducting the epigenome wide association study (EWAS), we performed two
156	unsupervised data reduction steps to reduce multiple testing burden and increase power. First, we utilized
157	CoMeBack to identify proximal CpG sites that exhibit highly correlated methylation patterns and
158	clustered these CpGs into co-methylated regions (CMRs) [16]. For each CMR, principal component
159	analysis was performed and the first component was used as a summary measure of the of DNAm within
160	each CMR. This step identified 57,146 CMRs representing the DNAm of 158,924 CpG sites. Many CpG
161	sites that were not clustered in CMRs and these were retained as individual CpG sites, for a total of
162	599,048 epigenetic loci (CpGs + CMRs). Next, since CpGs with low variability are more prone to be
163	affected by measurement error and may yield less reproducible findings [17], we excluded CpGs or

164 CMRs with low standard deviation (SD < 0.02). After performing these data reduction steps, 365,376 165 epigenetic loci were available for analyses – 49,470 CMRs and 315,906 individual CpGs. We conducted five EWAS to characterize the relationships between DNAm levels and the 166 concentrations of five individual PFAS chemicals in placental tissue. We used robust linear regression 167 168 models from the MASS package which implement M-estimation with Huber and bisquare weighting to 169 reduce the influence of outliers[18], to regress DNA methylation beta values on natural log transformed 170 PFAS concentrations. All models were adjusted for technical covariates and potential confounders that 171 were determined *a priori* based on a directed acyclic graph (DAG, **Supplemental Figure S1**). All models 172 were adjusted for maternal BMI (normal weight, overweight/obesity), maternal age at delivery, 173 gestational age at birth, maternal educational attainment, infant sex, DNA methylation batch, and 174 proportions of placental cell types (trophoblasts, stromal cells, Hofbauer cells, endothelial cells, nRBCs, 175 and syncytiotrophoblasts), which were estimated via the *planet* package in R [19]. We evaluated genomic 176 inflation factors and QQ-plots for evidence of inflation and calculated false-discovery rate (FDR) for each 177 PFAS EWAS, considering those associations with FDR q-values < 0.05 as statistically significant. 178 We then used secondary analyses to evaluate whether there was a mixture effect on DNA 179 methylation from simultaneous exposure to multiple PFAS congeners in the placenta. For this, we 180 performed a targeted analysis of the CpGs that were significantly associated with any one of the PFAS congeners from the primary EWAS. For these analyses we applied quantile g-computation, a parametric 181 generalized linear modelling approach that performs g-computation [20]. This method estimates the 182 183 overall effect of the placental PFAS mixture by simultaneously increasing all concentrations by one 184 quartile, while controlling for the same potential confounders and technical factors described above. In 185 addition to estimating the overall mixture effect, each PFAS component in the mixture is assigned a 186 partial positive or a partial negative weight, regardless of the direction and magnitude of the overall 187 mixture effect. All weights in the same direction sum to 1, indicating the relative contribution of an 188 individual PFAS towards that direction of effect on methylation for a given loci. Because the weights 189 represent relative contributions for only a particular direction of effect, the weights in a particular

190 direction should only be compared and be evaluated separately for each epigenetic loci. We performed 191 two quantile g-computation analysis to quantify the effect of placental PFAS exposure on each loci. In 192 our first approach, we did not allow for interaction between individual PFAS. In our second approach, we 193 allowed for the model to include all two-way interaction terms using bootstrapping. 194 Additionally, because emerging evidence suggests that developmental exposure to PFAS may 195 have sexually dimorphic effects on some outcomes [21], we explored whether there was any evidence of 196 sex-specific associations from the individual PFAS or from the PFAS mixture on DNAm. For these 197 analyses, we performed the untargeted EWAS for each of the 5 PFAS among females (N=63) and males 198 (N=88) separately. These models had the same covariate adjustments as above but did not include sex as 199 a covariate. 200 Last we performed functional enrichment analyses to test whether the sets of epigenetic loci that 201 we identified in our EWAS were components within broader biological processes or functions. We used 202 the missMethyl package in R to test for gene ontology (GO) term and Kyoto Encyclopedia of Genes and

203 Genomes (KEGG) pathway enrichment, since this method corrects for probe number bias [22].

204 **Results:**

205 Study Population

This study sample included mother-infant dyads from the Glowing Study for whom placental 206 207 DNAm and placental PFAS were quantified. As part of enrollment criteria, all mothers were self-reported 208 non-smokers and were second parity. The study sample (n=151) primarily represented healthy 209 pregnancies and birth outcomes (**Table 1**). The mean maternal age at the time of delivery was 30.5 years 210 (SD = 3.42 years) and most of the mothers had a college degree (66.9%) and self-identified as White 211 (86.1%). The 151 infants included 63 females and 88 males, who were born with an average gestation of 212 39.3 weeks (range 36.4 – 41.4 weeks). 213 Placental PFAS Quantification Concentrations of five PFAS were detectable in over 70% of placental samples: PFHxS, PFOS, 214 215 PFOA, PFNA, and PFDA. As displayed in Table 2, PFOS was detected at the highest rate and had the 216 highest average concentrations, while PFOA and PFHxS had the second and third highest concentrations. 217 Data were natural log-transformed prior to downstream analyses to deal with the right skewed 218 distributions but some distributions for LOD-imputed PFAS remain non-normal (Supplemental Figure 219 **S2**). The placental concentrations of these PFAS were moderately correlated with each other 220 (Supplemental Figure S3), with the strongest pairwise correlation between PFNA and PFDA (Spearman rho = 0.71), the weakest correlation between PFHxS and PFDA or PFNA (Spearman rho = 0.30), and 221 PFHxS generally exhibiting lower correlations with other PFAS. 222 223 Epigenome-Wide Association Study (EWAS) of Placental PFAS 224 We performed five EWAS, to estimate differences in DNA methylation across 365,376 epigenetic loci. Genomic inflation factors and QQ plots for each EWAS indicated minimal evidence of 225 226 inflation (Supplemental Figure S4). We identified differential methylation at 23 epigenetic loci (FDR q-227 values < 0.05; Figure 1) with PFHxS having the greatest number of associations (11 loci), followed by 228 PFNA (5 loci), PFOS (4 loci), PFOA (2 loci), and PFDA (1 loci) (Table 3). While the loci that were associated each of these five PFAS differed, the parameter estimates for their associations were very 229

highly correlated (**Supplemental Figure S5**). Parameter estimates for PFOS and PFNA exhibited the strongest correlations (Spearman rho = 0.93), while the parameter estimates for PFHxS with all other PFAS were the weakest, but still moderate-to-strong correlations (rho range 0.71 - 0.79). The overall EWAS output will be made publicly available upon publication.

234 Secondary PFAS Mixtures Analyses

235 Since our findings above show that PFAS concentrations in the placenta were moderately 236 correlated with each other, and the 23 loci that were associated with any PFAS exhibited correlated 237 effects on DNAm, we hypothesized that PFAS may not have independent effects on DNAm but instead 238 may have synergistic or cumulative effects. Thus, we examined whether placental DNAm levels at these 23 loci were significantly impacted by simultaneous exposure to PFAS. Using quantile g-computation, we 239 240 found that overall, a simultaneous increase in all five PFAS by one quartile was associated with reduced 241 methylation levels at 6 loci and with increased methylation levels at 6 loci in the placental tissue (Figure 2 and Table S1). Partial positive and negative weights from quantile g-computation show the proportion 242 243 of the effect in a particular direction associated with each PFAS. Some of the mixture results were similar 244 to the EWAS results for each PFAS, where PFHxS greatly contributed to the positive effects while PFOS, 245 PFOA, and PFNA primarily contributes to the negative direction (Figure 3).

246 However, multiple interesting findings emerged from the mixture analyses. For instance, PFOS had a negative weight for all loci for which there was a significant negative mixture effect, but other 247 248 PFAS had stronger negative weights for each of these negative mixture effects. Additionally, PFOS was 249 assigned a positive weight for 4 of the 6 loci with significant positive mixture effects, but only had the 250 strongest weight for cg14603624. Similarly, the PFOA weights aligned with the overall mixture effects 251 for all of the significant mixture effects, except for cg15641477, where it had an opposite direction of effect, and for cg10720382 where it was assigned a weight of zero. The other three PFAS had more 252 253 variation in their contributions to the significant mixture effects. Interestingly, among the loci with 254 significant mixture effects, only one exhibited the same direction of the weights for all five PFAS, cg17718899. This locus was only significantly associated (FDR < 0.05) with high PFOA levels in the 255

256	individual EWAS models, but in the mixture model all five PFAS had positive weights, with the strongest
257	positive contributions coming from PFOA, PFHxS, and PFNA, respectively. For most loci, 1, 2, or 3
258	PFAS were driving the majority of the directional effects, and other PFAS weights were close to zero or
259	in the opposite direction of the mixture effect.
260	When we tested for interactions between each PFAS included in the mixture, we observed that, a
261	simultaneous increase in all five PFAS by one quartile was linked with reduced methylation at
262	cg20856960 and cg11442048 via potential interactions (Supplementary Table S2). Interestingly, both
263	quantile g-computation approaches suggested that methylation levels at cg11442048 (annotated to
264	LOC100128568 and RFX2 genes on chr19) were reduced upon placental mixture PFAS exposure
265	suggesting that this may be an important target site for several PFAS.
266	Sex-Specific Analyses
267	We explored whether the effect of each individual PFAS on the placental methylome was differential
268	among males and females via stratified analyses (Supplementary Figure S6 and Table S1). We
269	observed that p-values tended to be smaller, effect sizes larger, and larger numbers of statistically
270	significant loci were identified in the sex-stratified models. Specifically, in sex stratified models, we
271	observed that increasing exposure to PFAS tended to be linked with substantially more methylation
272	perturbations among females than males. This was particularly apparent for PFHxS and PFOS levels,
273	which were associated with 644 and 232 loci respectively in females, and with 137 and 125 loci
274	respectively in males (FDR < 0.05).

275 Functional Enrichment Analyses

Last, we aimed to understand whether any GO terms or KEGG pathways were enriched among the epigenetic loci that were most differentially methylated with increasing PFAS concentrations. Since the 23 loci that yielded EWAS associations (FDR < 0.05) were only annotated to 10 genes, we expanded our gene list to include any loci that yielded an EWAS association p-value < 1.0e-05, which included 103 loci. No GO terms were significantly enriched after adjusting for bias and multiple testing. One KEGG

- 281 pathway was significantly enriched (FDR q-value < 0.05), Valine, leucine and isoleucine biosynthesis
- 282 (hsa00290).
- 283
- 284

285 **Discussion:**

286 We quantified 17 PFAS concentrations in placental tissue from the Glowing cohort of motherinfant dyads in the Central Arkansas region. We show that several placental PFAS concentrations are 287 288 associated with differential DNAm at several epigenetic loci. In our study, placental PFAS concentrations 289 were moderately correlated with each other. We found that PFHxS exhibited the largest number of 290 significant differentially methylated epigenetic loci. When we compared parameter estimates across 291 EWAS, while still correlated for multiple pairwise comparisons, the parameter estimates for PFHxS had 292 the weakest correlations with the parameter estimates for all other PFAS. Our secondary analyses with 293 mixture modeling revealed that 12 of the 23 tested sites exhibited significant mixture effects and that 294 PFOS and PFOA generally contributed to mixture effects in the same direction, whereas the other three 295 PFAS were more variable in their contributions to mixture effects. Additionally in the mixture analyses, 296 PFHxS was assigned strong weights in opposite directions of other PFAS for many of our identified loci. 297 These findings could suggest that PFOS and PFOA may have more synergistic or cumulative impact on 298 the placental methylome and that PFHxS has a more unique effect on the placental epigenome compared 299 to the other 4 PFAS that we tested. Notably, PFHxS has been a common replacement for PFOS and 300 PFOA, under the assumption that shorter chain PFAS may be less toxic than legacy PFAS [23]. PFHxS 301 was also very highly detected in the ground water at an air force base north of Little Rock, AR [24]. Thus, the potential impacts of prenatal PFAS exposure, and particularly PFHxS, are important for this and 302 303 similarly exposed populations.

The vast majority of epidemiologic studies have examined concentrations of PFAS in maternal samples, while only a handful have quantified placental PFAS concentrations, which may be more reflective of direct *in utero* exposure. We compared our placental PFAS levels to one other published study from a US cohort, where PFAS were quantified in placenta sampled between 2010 – 2011 in Durham, North Carolina. Complimentary to our findings, Hall et al. (2022) observed similar average placental concentrations of 4 PFAS, a similar correlation structure among these PFAS, and that PFOS had highest concentrations [25]. While Hall et al. did not examine placental epigenetic responses, they did

311	find that increasing concentrations of placental PFAS were associated with smaller birth size for
312	gestational age and that there may be some sex-specific effects on fetal growth [25].
313	Interestingly, several of the genes and epigenetic loci that we identified as differentially
314	methylated in association with increasing placental PFAS concentrations have been associated with other
315	endocrine disrupting chemicals and with cardiometabolic outcomes. For instance, multiple CpGs within
316	XKR6, among other CpGs and genes, were found to have lower DNA methylation levels among placenta
317	of newborns with selective fetal growth restriction [26]. Higher levels of maternal urinary bisphenol A
318	(BPA) concentrations were associated with lower DNA methylation of one CpG in XKR6 [27].
319	Additionally, maternal glucose concentrations during early pregnancy were associated with differences in
320	DNA methylation at one CpG in XKR6 [28]. Placental DNA methylation levels of CpGs in NAV2 have
321	previously been associated with maternal systolic blood pressure [29, 30]. The expression of KCNQ3 was
322	shown to be upregulated in placentas from mother with preeclampsia [31]. Notably, Early B Cell
323	Transcription Factor 1 (EBF1), annotated to cg14572446, has been associated with multiple traits
324	(GWAS catalog [32]), including anthropometrics, body composition, and lipid profiles, and CpGs
325	annotated to <i>EBF1</i> were also identified in the only other placental PFAS-EWAS to date [9]. Interestingly,
326	in our study, DNAm of cg14572446 within EBF1 was positively related to simultaneous increase in both
327	PFHxS and PFOA. In-vitro experiments showed that Bisphenol S (BPS) was associated with decreased
328	expression of MESP2 in preadipocytes [33]. While our functional enrichment analyses only yielded one
329	significantly enriched KEGG pathway – valine, leucine and isoleucine biosynthesis, it is of note that
330	several untargeted metabolomics studies of PFAS have identified this same pathway being perturbed with
331	PFAS exposure [34]. Prenatal exposure to PFAS has been associated with non-alcoholic fatty liver
332	disease in children, and perturbations to valine, leucine, isoleucine metabolism and biosynthesis, along
333	with other amino acids and lipids, were identified as potential intermediaries [35, 36]. In another study,
334	maternal plasma concentrations of PFAS were associated with perturbations to multiple amino acid
335	metabolism and biosynthesis pathways, with leucine, isoleucine, valine metabolism exhibiting the
336	greatest number of associations [37]. Circulating levels of valine, leucine, and isoleucine are also

important predictors or biomarkers of several cardiometabolic diseases [38]. Overall, many of the genesannotated to our PFAS-associated epigenetic loci serve important roles in cardiometabolic health, and

- some of these have been shown to be affected by other endocrine disrupting chemicals.

340 In addition to cardiometabolic health, some of these genes are important in neurodevelopment. In 341 a rat model, prenatal BPA exposure was associated with altered expression of KCNQ3 in the amygdala of 342 exposed females [39], and KCNO3 may have important functions in some neurodevelopmental outcomes 343 [40]. NAV2 guides axonal outgrowth and plays critical roles in early cerebellar development [41], while 344 *PLEKHG2* is also involved in axonal growth, and impaired function is likely involved in neuronal 345 disorders [42]. Importantly, our study did not examine whether DNAm at our PFAS-associated epigenetic loci was associated with the expression of the genes or metabolites that we describe above. Additionally, 346 347 many genes have pleiotropic effects with roles in numerous biological processes and phenotypes. The 348 actual genomic and phenotypic consequences of our observed differential DNAm are not clear, but these 349 prior studies provide important context about the biological process and potential phenotypic outcomes 350 that may be involved in such responses to prenatal PFAS exposures.

351 Our study contributes to the emerging evidence that PFAS impact the epigenetic regulation of the 352 placenta and these findings may have implications for cardiometabolic health or other children's health 353 outcomes. Importantly, our study utilized placental PFAS concentrations to study the impacts on the 354 placental methylome, allowing for a more proximal exposure biomarker that may also be highly impactful on the *in-utero* environment. However, there are several limitations of this work that should be considered 355 356 when interpreting our findings. While we utilized two data reduction steps to improve power and applied 357 an FDR correction to identify significant differential DNAm, our sample size was modest for an 358 epigenome wide approach (n=151). This moderate sample size also resulted in reduced statistical power, 359 particularly in the sex-stratified analyses. However, our sex-stratified analyses are hypothesis-generating, 360 and suggest that future studies of placental PFAS and DNAm should explicitly plan for and perform 361 analyses to identify sex-specific effects. Additionally, the Glowing Cohort represents a healthy population 362 in central Arkansas. While this reduces potential generalizability to other populations, our study also

represents an important contribution to the characterization of risk factors for adverse child growth and
cardiometabolic health in a population that has potentially high exposure to some PFAS and high rates of
low birthweight. Despite some limitations, our study provides a substantial contribution towards
understanding the placental epigenetic responses to PFAS.

367

368 Conclusions

369 We performed an EWAS of placental PFAS levels associated with placental DNAm in a healthy 370 cohort of mother-infant dyads from Arkansas. We found that numerous epigenetic loci in the placenta 371 appear to be perturbed in association with increasing PFAS concentrations, and that PFHxS had the most pronounced effect in this study. Mixture analyses revealed that PFOA and PFOS tended to have 372 consistent directions and possibly cumulative effects on several epigenetic loci, while PFHxS tended to 373 374 perturb the placental methylome more independently. Additionally, we provide suggestive evidence that 375 sex-specific associations are an important consideration for future studies. The genes that are annotated to our identified loci predominantly play important roles in growth and cardiometabolic health, but we also 376 377 identified several genes that are important in neurodevelopment. These findings can provide insights into 378 the mechanisms through which prenatal PFAS exposures impact birth outcomes and children's health.

380 CRediT authorship contribution statement

381	Todd M Everson : Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology,
382	Writing – original draft, Writing – review & editing. Neha Sehgal: Formal analysis, Methodology,
383	Visualization, Writing – original draft, Writing – review & editing. Dana Boyd Barr: Data curation,
384	Methodology, Writing – review & editing. Parinya Panuwet: Formal analysis. Volha Yakimavets:
385	Formal analysis. Cynthia Perez: Formal Analysis. Stephanie M. Eick: Methodology, Writing – review
386	& editing. Karitk Shankar: Formal Analysis, Methodology, Data Curation, Writing – review & editing.
387	Kevin J Pearson: Funding Acquisition, Project administration, Writing – review & editing. Aline
388	Andres: Data Curation, Program Administration, Funding acquisition, Writing – review & editing.
389	
390	Declaration of competing interest
391	The authors declare that they have no known competing financial interests or personal relationships that
392	could have appeared to influence the work reported in this paper.
393	
394	Acknowledgments
395	We acknowledge all the families who chose to participate in this study as well as the Arkansas Children's
396	Nutrition Center team for the data and samples acquisition for the Glowing Study.
397	
398	Funding statement
399	This work was supported by funding from the National Institute of Environmental Health Sciences,
400	NIH/NIEHS [R01 ES032176; MPIs: Andres, Everson, & Pearson], the HERCULES Center [P30
401	ES019776; Everson, Barr, Eick] and the USDA-ARS [6026-51000-012-06S; Glowing cohort].
402	Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the
403	views NIH.
404	
405	Data availability

406 Raw and processed epigenetic data will be made available on NCBI GEO upon publication.

409 **References:** 410 Evich MG, Davis MJB, McCord JP, Acrey B, Awkerman JA, Knappe DRU, Lindstrom AB, Speth TF, Tebes-Stevens C, 411 1. Strynar MJ et al: Per- and polyfluoroalkyl substances in the environment. Science 2022, 375(6580):eabg9065. 412 Fenton SE, Ducatman A, Boobis A, DeWitt JC, Lau C, Ng C, Smith JS, Roberts SM: Per- and Polyfluoroalkyl 413 2. 414 Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing 415 Future Research. Environ Toxicol Chem 2021, 40(3):606-630. 416 3. Mamsen LS, Bjorvang RD, Mucs D, Vinnars MT, Papadogiannakis N, Lindh CH, Andersen CY, Damdimopoulou P: Concentrations of perfluoroalkyl substances (PFASs) in human embryonic and fetal organs from first, second, 417 418 and third trimester pregnancies. Environ Int 2019, 124:482-492. Szilagyi JT, Avula V, Fry RC: Perfluoroalkyl Substances (PFAS) and Their Effects on the Placenta, Pregnancy, and 419 4. Child Development: a Potential Mechanistic Role for Placental Peroxisome Proliferator-Activated Receptors 420 421 (PPARs). Current environmental health reports 2020, 7(3):222-230. 5. Evans N, Conley JM, Cardon M, Hartig P, Medlock-Kakaley E, Gray LE, Jr.: In vitro activity of a panel of per- and 422 423 polyfluoroalkyl substances (PFAS), fatty acids, and pharmaceuticals in peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, and estrogen receptor assays. Toxicology and applied pharmacology 424 425 2022, 449:116136. Matsuda S, Kobayashi M, Kitagishi Y: Expression and Function of PPARs in Placenta. PPAR Res 2013, 426 6. 427 2013:256508. 428 7. Lapehn S, Paquette AG: The Placental Epigenome as a Molecular Link Between Prenatal Exposures and Fetal 429 Health Outcomes Through the DOHaD Hypothesis. Curr Environ Health Rep 2022, 9(3):490-501. 430 Wang H, Li W, Yang J, Wang Y, Du H, Han M, Xu L, Liu S, Yi J, Chen Y et al: Gestational exposure to perfluoroalkyl 8. substances is associated with placental DNA methylation and birth size. Sci Total Environ 2023, 858(Pt 431 1):159747. 432 433 9. Ouidir M, Mendola P, Buck Louis GM, Kannan K, Zhang C, Tekola-Ayele F: Concentrations of persistent organic pollutants in maternal plasma and epigenome-wide placental DNA methylation. Clin Epigenetics 2020, 434 12(1):103. 435 436 10. Xie Z, Sun S, Ji H, Miao M, He W, Song X, Cao W, Wu Q, Liang H, Yuan W: Prenatal exposure to per- and 437 polyfluoroalkyl substances and DNA methylation in the placenta: A prospective cohort study. J Hazard Mater 438 2024, 463:132845. 439 Diaz EC, Williams DK, Howie EK, Borsheim E, Andres A: Offspring sex modifies the association between early-11. 440 pregnancy adiposity and 2-year-old physical activity-The Glowing Study. Int J Obes (Lond) 2024, 48(4):542-549. 441 12. Heard-Lipsmeyer ME, Diaz EC, Sims CR, Sobik SR, Ruebel ML, Thakali KM, Krukowski RA, Cleves M, Borsheim E, Shankar K, Andres A: Maternal Adiposity is Associated with Fat Mass Accretion in Female but not Male 442 443 Offspring During the First 2 Years of Life. Obesity 2020, 28(3):624-630. 444 13. Fortin JP, Triche TJ, Jr., Hansen KD: Preprocessing, normalization and integration of the Illumina 445 HumanMethylationEPIC array with minfi. Bioinformatics (Oxford, England) 2017, 33(4):558-560. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S: A beta-mixture quantile 446 14. normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. 447 448 Bioinformatics 2013, 29(2):189-196. 449 15. Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, Van Djik S, Muhlhausler B, Stirzaker C, 450 Clark SJ: Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome biology 2016, 17(1):208. 451 Gatev E, Gladish N, Mostafavi S, Kobor MS: CoMeBack: DNA methylation array data analysis for co-methylated 452 16. 453 regions. Bioinformatics 2020, 36(9):2675-2683. Logue MW, Smith AK, Wolf EJ, Maniates H, Stone A, Schichman SA, McGlinchey RE, Milberg W, Miller MW: The 454 17. correlation of methylation levels measured using Illumina 450K and EPIC BeadChips in blood samples. 455 456 Epigenomics 2017, 9(11):1363-1371. 457 18. Venables WN, Ripley BD: Modern applied statistics with S, Fourth Edition edn: Springer; 2002. 19. Yuan V, Hui D, Yin Y, Penaherrera MS, Beristain AG, Robinson WP: Cell-specific characterization of the placental 458 459 methylome. BMC Genomics 2021, 22(1):6.

460 461	20.	Keil AP, Buckley JP, O'Brien KM, Ferguson KK, Zhao S, White AJ: A Quantile-Based g-Computation Approach to
401	21	Sychoda LK Ishikawa T. Dolinov DC: Developmental toxicant exposures and sox specific effects on enigenetic
462 463	21.	programming and cardiovascular health across generations. Environ Epigenet 2022, 8(1):dvac017.
464	22.	Phipson B, Maksimovic J, Oshlack A: missMethyl: an R package for analyzing data from Illumina's
465		HumanMethylation450 platform. Bioinformatics (Oxford, England) 2016, 32(2):286-288.
466	23.	Ateia M, Maroli A, Tharayil N, Karanfil T: The overlooked short- and ultrashort-chain poly- and perfluorinated
467		substances: A review. Chemosphere 2019, 220:866-882.
468	24.	PFAS Contamination in the U.S. (February 5, 2024) [https://www.ewg.org/interactive-
469		maps/pfas_contamination/map/]
470	25.	Hall SM, Zhang S, Hoffman K, Miranda ML, Stapleton HM: Concentrations of per- and polyfluoroalkyl
471		substances (PFAS) in human placental tissues and associations with birth outcomes. Chemosphere 2022,
472		295 :133873.
473	26.	Shi D, Zhou X, Cai L, Wei X, Zhang L, Sun Q, Zhou F, Sun L: Placental DNA methylation analysis of selective fetal
474		growth restriction in monochorionic twins reveals aberrant methylated CYP11A1 gene for fetal growth
475		restriction. FASEB J 2023, 37 (10):e23207.
476	27.	McCabe CF, Padmanabhan V, Dolinoy DC, Domino SE, Jones TR, Bakulski KM, Goodrich JM: Maternal
477		environmental exposure to bisphenols and epigenome-wide DNA methylation in infant cord blood. Environ
478		Epigenet 2020, 6 (1):dvaa021.
479	28.	Geurtsen ML, Jaddoe VWV, Gaillard R, Felix JF: Associations of maternal early-pregnancy blood glucose and
480		insulin concentrations with DNA methylation in newborns. Clin Epigenetics 2020, 12 (1):134.
481	29.	Broseus L, Vaiman D, Tost J, Martin CRS, Jacobi M, Schwartz JD, Beranger R, Slama R, Heude B, Lepeule J:
482		Maternal blood pressure associates with placental DNA methylation both directly and through alterations in
483		cell-type composition. BMC Med 2022, 20 (1):397.
484	30.	Workalemahu T, Ouidir M, Shrestha D, Wu J, Grantz KL, Tekola-Ayele F: Differential DNA Methylation in
485		Placenta Associated With Maternal Blood Pressure During Pregnancy. Hypertension 2020, 75(4):1117-1124.
486	31.	Mistry HD, McCallum LA, Kurlak LO, Greenwood IA, Broughton Pipkin F, Tribe RM: Novel expression and
487		regulation of voltage-dependent potassium channels in placentas from women with preeclampsia
488		Hypertension 2011, 58 (3):497-504.
489	32.	Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, Groza T, Gunes O, Hall P, Hayhurst J et al: The NHGRI-EBI
490		GWAS Catalog: knowledgebase and deposition resource. Nucleic acids research 2023, 51(D1):D977-D985.
491	33.	Boucher JG, Gagne R, Rowan-Carroll A, Boudreau A, Yauk CL, Atlas E: Bisphenol A and Bisphenol S Induce
492		Distinct Transcriptional Profiles in Differentiating Human Primary Preadipocytes. PloS one 2016,
493		11 (9):e0163318.
494	34.	India-Aldana S, Yao M, Midya V, Colicino E, Chatzi L, Chu J, Gennings C, Jones DP, Loos RJF, Setiawan VW <i>et al</i> :
495		PFAS Exposures and the Human Metabolome: A Systematic Review of Epidemiological Studies. Curr Pollut Rep
496		2023, 9 (3):510-568.
497	35.	Jin R, McConnell R, Catherine C, Xu S, Walker DI, Stratakis N, Jones DP, Miller GW, Peng C, Conti DV et al:
498		Perfluoroalkyl substances and severity of nonalcoholic fatty liver in Children: An untargeted metabolomics
499		approach. Environ Int 2020, 134 :105220.
500	36.	Stratakis N, D VC, Jin R, Margetaki K, Valvi D, Siskos AP, Maitre L, Garcia E, Varo N, Zhao Y <i>et al</i> : Prenatal
501		Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children.
502		Hepatology 2020, 72 (5):1758-1770.
503	37.	Prince N, Begum S, Minguez-Alarcon L, Genard-Walton M, Huang M, Soeteman DI, Wheelock C, Litonjua AA,
504		Weiss ST, Kelly RS, Lasky-Su J: Plasma concentrations of per- and polyfluoroalkyl substances are associated
505		with perturbations in lipid and amino acid metabolism. Chemosphere 2023, 324 :138228.
506	38.	Fine KS, Wilkins JT, Sawicki KT: Circulating Branched Chain Amino Acids and Cardiometabolic Disease. J Am
507		Heart Assoc 2024, 13 (7):e031617.
508	39.	Arambula SE, Jima D, Patisaul HB: Prenatal bisphenol A (BPA) exposure alters the transcriptome of the neonate
509		rat amygdala in a sex-specific manner: a CLARITY-BPA consortium study. Neurotoxicology 2018, 65:207-220.
510	40.	Sands TT, Miceli F, Lesca G, Beck AE, Sadleir LG, Arrington DK, Schonewolf-Greulich B, Moutton S, Lauritano A,
511		Nappi P et al: Autism and developmental disability caused by KCNQ3 gain-of-function variants. Ann Neurol
512		2019, 86 (2):181-192.

- 41. Accogli A, Lu S, Musante I, Scudieri P, Rosenfeld JA, Severino M, Baldassari S, Iacomino M, Riva A, Balagura G et
- 514 *al*: Loss of Neuron Navigator 2 Impairs Brain and Cerebellar Development. *Cerebellum* 2023, **22**(2):206-222.
- 42. Nishikawa M, Ito H, Tabata H, Ueda H, Nagata KI: **Impaired Function of PLEKHG2, a Rho-Guanine Nucleotide**-
- 516 Exchange Factor, Disrupts Corticogenesis in Neurodevelopmental Phenotypes. *Cells* 2022, **11**(4).
- 517
- 518
- 519

- Tables and Figures for "Placental PFAS concentrations associated with perturbations of placental DNA
 methylation".
- 522
- 523

524 Table 1: Distribution of demographic variables in the Glowing study, 2010-2014.

	Overall	
	(N=151)	
Infant Sex		
Female	63 (41.7%)	
Male	88 (58.3%)	
BMI Enrollment Category		
Pregnant women with normal weight	74 (49.0%)	
Pregnancy women with overweight or obesity	77 (51.0%)	
Maternal Race		
White	130 (86.1%)	
Non-White	21 (13.9%)	
Maternal Educational Attainment		
College Degree	101 (66.9%)	
No College Degree	50 (33.11%)	
Maternal Age at Delivery (years)		
Mean (SD)	30.5 (3.42)	
Median [Min, Max]	30.2 [22.5, 42.4]	
Gestational Age at Birth (weeks)		
Mean (SD)	39.3 (0.85)	
Median [Min, Max]	39.3 [36.4, 41.4]	

525

Table 2: Distribution of placental per- and polyfluoroalkyl substances levels (ng/g) in the Glowing study, 2010 2014.

				-			Percentiles	5	
	Above Limit of Detection (%)	N	Geometric Mean	Geometric Standard Deviation	5%	25%	50%	75%	95%
PFHxS	83.4	151	0.05	2.82	0.01	0.04	0.05	0.08	0.23
PFOA	74.8	151	0.05	2.87	0.01	0.01	0.07	0.11	0.24
PFNA	98.0	151	0.05	1.86	0.02	0.03	0.05	0.08	0.12
PFOS	98.7	151	0.38	2.01	0.12	0.26	0.43	0.58	0.97
PFDA	68.9	151	0.025	2.48	0.01	0.01	0.04	0.05	0.07

Table 3: Placental EWAS results for PFOS, PFOA, PFHxS, PFDA, and PFNA, for the 23 loci that were associated
with at least one PFAS; Beta represents the estimated differential methylation with a 1-ln increase in PFAS and
bold text is used to highlight those associations that yielded FDR q-values (q-val.) < 0.05; Loci that were CMRs list
multiple CpG IDs.

	PFOS		PFOA		PFHxS		PFDA		PFNA	
Epigenetic Loci	Beta	q-val.								
cg01793178	0.0211	0.03	0.0049	1.00	0.0108	0.22	-0.0007	0.99	0.0138	1.00
cg15438999	-0.0136	0.04	-0.0072	0.94	-0.0037	0.85	-0.0111	0.31	-0.0154	0.80
cg24634055	0.0218	0.04	0.0016	1.00	0.0048	0.86	0.0074	0.83	0.0048	1.00
cg14603624	0.0323	0.04	0.0063	1.00	0.0102	0.76	0.0123	0.79	0.0216	1.00
cg18434560	-0.0122	0.18	-0.0097	0.03	-0.0070	0.33	-0.0039	0.85	-0.0107	0.89
cg17718899	0.0082	0.38	0.0067	0.03	0.0051	0.46	0.0035	0.82	0.0081	0.61
cg00011173	-0.0111	0.46	-0.0046	1.00	0.0011	0.96	-0.0064	0.69	-0.0180	0.03
cg24371331	-0.0082	0.77	-0.0048	0.99	-0.0006	0.97	-0.0073	0.38	-0.0132	0.05
cg15641477	-0.0253	0.54	-0.0086	1.00	-0.0083	0.82	-0.0186	0.46	-0.0393	0.02
cg20856960; cg22399868	-0.0095	1.00	-0.0043	1.00	-0.0014	0.96	-0.0073	0.68	-0.0191	0.05
cg13318071; cg18107425	-0.0077	0.10	-0.0022	1.00	-0.0032	0.61	-0.0033	0.75	-0.0096	0.02
cg11442048	-0.0052	1.00	-0.0064	0.99	-0.0032	0.83	-0.0116	0.02	-0.0080	1.00
cg08889114	0.0029	1.00	0.0060	1.00	0.0119	0.04	0.0023	0.97	-0.0001	1.00
cg21845400	-0.0002	1.00	0.0036	1.00	0.0148	0.02	-0.0004	1.00	-0.0020	1.00
cg09786142	0.0122	0.66	0.0113	0.55	0.0130	0.03	0.0056	0.89	0.0074	1.00
cg22420548	0.0070	1.00	0.0059	1.00	0.0159	0.02	0.0034	0.96	0.0079	1.00
cg14572446	0.0155	1.00	0.0116	1.00	0.0303	0.04	0.0091	0.90	0.0079	1.00
cg14434870	0.0077	1.00	-0.0005	1.00	0.0134	0.04	0.0032	0.96	-0.0010	1.00
cg04962865	0.0319	0.99	0.0175	1.00	0.0325	0.04	0.0083	0.95	0.0221	1.00
cg26670786	0.0090	1.00	0.0052	1.00	0.0138	0.01	0.0022	0.97	0.0050	1.00
cg10720382	0.0053	1.00	0.0042	1.00	0.0084	0.03	0.0024	0.93	0.0039	1.00
cg22921147	0.0105	1.00	0.0020	1.00	0.0153	0.01	-0.0002	1.00	0.0037	1.00
cg21880197	-0.0045	1.00	-0.0026	1.00	-0.0103	0.04	-0.0027	0.95	-0.0037	1.00

541 Table 4: Genomic annotations for 23 CpGs associated with any of PFOS, PFOA, PFHxS, PFDA, or PFNA.

_

542

Epigenetic loci	Gene	Chromosome
cg01793178	Intergenic	chr1
cg15438999	Intergenic	chr2
cg24634055	XKR6	chr8
cg14603624	Intergenic	chr9
cg18434560	Intergenic	chr11
cg17718899	Intergenic	chr13
cg00011173	Intergenic	chr18
cg24371331	PLEKHG2	chr19
cg15641477	DDRGK1	chr20
cg20856960	NAV2	chr11
cg13318071	MESP2	chr15
cg11442048	LOC100128568;RFX2	chr19
cg08889114	Intergenic	chr3
cg21845400	Intergenic	chr4
cg09786142	LINC01511	chr5
cg22420548	Intergenic	chr5
cg14572446	EBF1	chr5
cg14434870	Intergenic	chr6
cg04962865	Intergenic	chr8
cg26670786	KCNQ3	chr8
cg10720382	Intergenic	chr9
cg22921147	Intergenic	chr12
cg21880197	Intergenic	chr14

543

_ . .

544

Figure 1: Volcano plot for the associations between increasing concentrations of placental per- and polyfluoroalkyl substances (PFAS) levels with placental DNA methylation levels for the 23 CpGs that were significantly impacted by any one of the five PFAS in the Glowing study (N=151), 2010-2014.



Note: All models adjusted for maternal BMI (normal weight or overweight/obesity), maternal age at delivery, gestational age at birth, maternal educational attainment, infant sex, DNA methylation batch, and proportions of placental cell types (trophoblasts, stromal cells, Hofbauer cells, endothelial cells, nRBCs, and syncytiotrophoblasts). Increased or reduced methylation is based on whether the association was above or below 0, respectively and the FDR q-values < 0.05.





Note: All models adjusted for maternal BMI (normal weight versus overweight/obesity), maternal age at delivery, gestational age at birth, maternal educational attainment, infant sex, DNA methylation batch, and proportions of placental cell types (trophoblasts, stromal cells, Hofbauer cells, endothelial cells, nRBCs, and syncytiotrophoblasts). Increased or reduced methylation is based on whether the association was above or below 0, respectively and the p-values < 0.05.

Figure 3: Positive and negative weights showing the partial effects of placental per- and polyfluoroalkyl substances (PFAS in ng/g) on individual placental DNA methylation levels of the 23 CpGs that were significantly impacted by any one of the five PFAS in linear regression models, estimated using quantile g-computation, overall (N=151) in the Glowing study, 2010-2014.

		Weig	hts -1.0 -0.5 0.0	0.5 1.0		
			Overall			
MESP2 - chr15 - cg1331	8071 - 0.35	0.65	-0.21	-0.73	-0.06	H
NAV2 - chr11 - cg2085	6960 0.01	0.68	0.32	-0.8	-0.19	h.
Intergenic - chr14 - cg2188	0197 - 0.83	0.17	-0.69	-0.1	-0.22	Neg
PLEKHG2 - chr19 - cg24371	331 -0.13	0	1	-0.6	-0.27	gative
on Intergenic - chr18 - cg00011	173 -0.18	0.35	0.65	-0.59	-0.23	e Ass
L Intergenic - chr2 - cg15438	9990.11	0.32	0.68	-0.52	-0.37	socia
EUC100128568 RFX2 - chr19 - cg1144	20480.22	-0.62	0.31	0.69	-0.16	tions
Intergenic - chr11 - cg18434	-0.75	0.28	-0.01	0.72	-0.25	
DDRGK1 - chr20 - cg15641	477 - 1	-0.33	-0.04	-0.37	-0.26	
Intergenic - chr8 - cg04962	865 - 0.39	-1	0.29	0.01	0.31	
م ه EBF1 - chr5 - cg14572	446 0.37	-0.94	0.63	0	-0.06	-
Intergenic - chr9 - cg14603	624 0.11	0.16	-1	0	0.73	
ପ୍ର LINC01511 - chr5 - cg09786	6142 0.44	-0.96	0.34	-0.04	0.22	-
Intergenic - chr12 - cg2292	- 11470.25	0.17	0.45	-0.75	0.37	
Intergenic - chr13 - cg17718	0.45	0.14	0.32	0.01	0.08	Positi
KCNQ3 - chr8 - cg2667	0786- 0.09	-0.63	0.77	0.14	-0.37	Ve A
Intergenic - chr5 - cg2242	.05480.7	-0.25	0.74	0.26	-0.05	SSOC
lntergenic - chr1 - cg0179	31780.35	-0.65	0.53	0.35	0.12	iatio
Intergenic - chr9 - cg10720	0382 - 0	-0.59	0.92	0.08	-0.41	ns
Intergenic - chr3 - cg0888	9114 - 0.44	0.18	0.37	-1	0.01	
Intergenic - chr6 - cg1443	48700.56	-0.13	0.91	-0.31	0.09	
XKR6 - chr8 - cg2463	40550.51	-0.19	-0.17	-0.14		
Intergenic - chr4 - cg2184	5400 0.19	-0.1	1	-0.29	-0.41	
	InLPFOA	InPFDA	InPFHxS	InPFNA	InsPFOS	

Note: Shown are the partial plots from the quantile g-computation for the 23 loci that were statistically significantly (i.e., FDR q-values < 0.05) associated with any one of the PFAS EWAS. Epigenetic loci are ordered (on the y-axis) by largest to smallest mixture effect estimate of quantile g-computation and are bolded if the mixture effect was statistically significant (p < 0.05) and the y-axis is grouped based on whether the overall mixture effect of PFAS on the methylation levels of a particular loci was positive (i.e., increased methylation; orange) or negative (i.e., reduced methylation; purple). Within each row, the purple hued boxes show the negative weights whereas, the brown-orange hued boxes show the positive weights in a row together sum to 1 whereas, all positive weights in a row sum to 1. The weights correspond to the effect size relative to other's effects in the same direction and should not be directly compared across loci. All models adjusted for maternal BMI (normal weight versus overweight/obesity), maternal age at delivery, gestational age at birth, maternal educational attainment, infant sex, DNA methylation batch, and proportions of placental cell types (trophoblasts, stromal cells, Hofbauer cells, endothelial cells, nRBCs, and syncytiotrophoblasts)